These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2906888)

  • 41. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.
    Ireland A; Mason CH; Jewell DP
    Gut; 1988 Jun; 29(6):835-7. PubMed ID: 2898422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
    Kimura I; Kawasaki M; Matsuda A; Kataoka M; Kokurba Y
    Arzneimittelforschung; 1998 Dec; 48(12):1163-7. PubMed ID: 9893931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
    Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial.
    Gilat T; Suissa A; Leichtman G; Delpre G; Pavlotzky M; Grossman A; Fireman Z
    J Clin Gastroenterol; 1987 Aug; 9(4):415-7. PubMed ID: 2888801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid].
    Maier K; Frühmorgen P; Bode JC; Heller T; von Gaisberg U; Klotz U
    Dtsch Med Wochenschr; 1985 Mar; 110(10):363-8. PubMed ID: 2857633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.
    Mantzaris GJ; Archavlis E; Christoforidis P; Kourtessas D; Amberiadis P; Florakis N; Petraki K; Spiliadi C; Triantafyllou G
    Am J Gastroenterol; 1997 Mar; 92(3):454-6. PubMed ID: 9068468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid].
    Schölmerich J; Gerok W
    Wien Klin Wochenschr; 1986 Nov; 98(22):762-9. PubMed ID: 2880425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A polymeric drug for treatment of inflammatory bowel disease.
    Brown JP; McGarraugh GV; Parkinson TM; Wingard RE; Onderdonk AB
    J Med Chem; 1983 Sep; 26(9):1300-7. PubMed ID: 6136612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review].
    Van Gossum A
    Acta Gastroenterol Belg; 1992; 55(5-6):462-71. PubMed ID: 1363167
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
    Maier K; Fischer C; Klotz U; Heinkel K
    Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Efficacy and tolerability of 5-aminosalicylic acid in the short-term treatment of ulcerative rectocolitis during the mild or moderate stage].
    Bresci G; Carrai M; Venturini G; Gambardella L
    Minerva Dietol Gastroenterol; 1990; 36(1):31-3. PubMed ID: 1970855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial.
    Feurle GE; Theuer D; Velasco S; Barry BA; Wördehoff D; Sommer A; Jantschek G; Kruis W
    Gut; 1989 Oct; 30(10):1354-61. PubMed ID: 2684804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [New treatments of hemorrhagic rectocolitis].
    Rambaud JC
    Ann Gastroenterol Hepatol (Paris); 1988; 24(4):173-7. PubMed ID: 2901821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis.
    Zinberg J; Molinas S; Das KM
    Am J Gastroenterol; 1990 May; 85(5):562-6. PubMed ID: 2337059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.
    Dew MJ; Harries AD; Evans N; Evans BK; Rhodes J
    Br Med J (Clin Res Ed); 1983 Jul; 287(6384):23-4. PubMed ID: 6134565
    [No Abstract]   [Full Text] [Related]  

  • 59. Chloroquine for mild to moderately active ulcerative colitis: comparison with sulfasalazine.
    Goenka MK; Kochhar R; Tandia B; Mehta SK
    Am J Gastroenterol; 1996 May; 91(5):917-21. PubMed ID: 8633581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral mesalamine for ulcerative colitis.
    Med Lett Drugs Ther; 1992 Aug; 34(877):80-1. PubMed ID: 1353858
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.